Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23298998 | 0.84 | RAB9A (0.45) | HRH4TRPA1MAPK1NPC1RAB9A | |
| SCHEMBL22075474 | 0.81 | MAPK1 (0.47) | HRH4HRH1HTR2AMAPK1MAPT | |
| SCHEMBL14999657 | 0.81 | CYP2A6 (0.46) | HRH4MAOANOS3NOS1NOS2 | |
| SCHEMBL21165415 | 0.80 | HRH4 (0.38) | HRH4TRPA1HRH1HTR2AMAPK1 | |
| SCHEMBL8207110 | 0.76 | HRH4 (0.50) | HRH4MAOATRPA1HRH1HTR2A | |
| SCHEMBL8177168 | 0.76 | NOS3 (0.42) | HRH4MAOATRPA1NOS3NOS1 | |
| SCHEMBL1772613 | 0.76 | HRH4 (0.50) | HRH4MAOATRPA1HRH1HTR2A | |
| SCHEMBL22046433 | 0.76 | ALDH1A1 (0.43) | HRH4MAOAHRH1HTR2AMAPK1 | |
| SCHEMBL12083998 | 0.76 | HRH4 (0.50) | HRH4MAOATRPA1HRH1HTR2A | |
| SCHEMBL8045731 | 0.76 | HRH4 (0.50) | HRH4MAOATRPA1HRH1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | claimed |
| EP-1562946-B1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | claimed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | disclosed |
| EP-2190434-B1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | HRH4 3527/4885MAOA 54/4885TRPA1 4346/4885 |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | HRH4 1930/4885MAOA 654/4885TRPA1 3661/4885 |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | HRH4 1143/4885MAOA 653/4885TRPA1 3114/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | HRH4 1189/4885MAOA 1093/4885TRPA1 4839/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | HRH4 675/4885MAOA 243/4885TRPA1 4876/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | HRH4 3965/4885MAOA 1937/4885TRPA1 4766/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | HRH4 210/4885MAOA 572/4885TRPA1 3715/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | HRH4 1854/4885MAOA 3471/4885TRPA1 4835/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | HRH4 1919/4885MAOA 3760/4885TRPA1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.